{"transactions":[{"id":753195,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42016,"kind":"person","name":"Coveney Kevin Michael","position":1,"cik":"0001967056","reported_name":"Coveney Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-03T20:34:56.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":133333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":180746,"source":{"system":"sec-edgar","filing":"0001967056-26-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000196705626000003/ownership.xml","form_type":"4"}},{"id":753193,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-03T20:32:23.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":201124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":271479,"source":{"system":"sec-edgar","filing":"0001883914-26-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000188391426000003/ownership.xml","form_type":"4"}},{"id":753194,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42015,"kind":"person","name":"PASQUALONE FRANK","position":1,"cik":"0001597334","reported_name":"PASQUALONE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T20:30:34.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":18518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":26423,"source":{"system":"sec-edgar","filing":"0001597334-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000159733426000002/ownership.xml","form_type":"4"}},{"id":753192,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42013,"kind":"person","name":"WEBB MICHAEL D","position":1,"cik":"0001239463","reported_name":"WEBB MICHAEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T20:29:56.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":18518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":26416,"source":{"system":"sec-edgar","filing":"0001239463-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000123946326000002/ownership.xml","form_type":"4"}},{"id":753190,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42011,"kind":"person","name":"Schabacker Marcus","position":1,"cik":"0001645282","reported_name":"Schabacker Marcus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T20:27:08.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":18518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":26418,"source":{"system":"sec-edgar","filing":"0001645282-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000164528226000002/ownership.xml","form_type":"4"}},{"id":753191,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42012,"kind":"person","name":"Kegler George A.","position":1,"cik":"0001761753","reported_name":"Kegler George A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T20:25:22.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":18518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":26418,"source":{"system":"sec-edgar","filing":"0001761753-26-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000176175326000003/ownership.xml","form_type":"4"}},{"id":753189,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42010,"kind":"person","name":"DeWitt Sheila","position":1,"cik":"0002025032","reported_name":"DeWitt Sheila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-03T20:23:09.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":18518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":26306,"source":{"system":"sec-edgar","filing":"0002025032-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000202503226000002/ownership.xml","form_type":"4"}},{"id":753188,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2026-06-03T20:22:31.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the \"Reverse Stock Split\"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":27755,"source":{"system":"sec-edgar","filing":"0001883966-26-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000188396626000003/ownership.xml","form_type":"4"}},{"id":957626,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42010,"kind":"person","name":"DeWitt Sheila","position":1,"cik":"0002025032","reported_name":"DeWitt Sheila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T21:42:13.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock\nwere reclassified as one share of common stock (the \"January Reverse Stock Split\"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted\nbasis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the\"October Reverse Stock Split\"\ntogether with the January Reverse Stock Split, the \"Reverse Stock Splits\"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock\nSplits."}],"balance_after":7788,"source":{"system":"sec-edgar","filing":"0001193125-25-337184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337184/ownership.xml","form_type":"4"}},{"id":957625,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42012,"kind":"person","name":"Kegler George A.","position":1,"cik":"0001761753","reported_name":"Kegler George A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T21:41:22.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock\nwere reclassified as one share of common stock (the \"January Reverse Stock Split\"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted\nbasis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the\"October Reverse Stock Split\"\ntogether with the January Reverse Stock Split, the \"Reverse Stock Splits\"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock\nSplits."}],"balance_after":7900,"source":{"system":"sec-edgar","filing":"0001193125-25-337182","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337182/ownership.xml","form_type":"4"}},{"id":957624,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42015,"kind":"person","name":"PASQUALONE FRANK","position":1,"cik":"0001597334","reported_name":"PASQUALONE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T21:40:31.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock\nwere reclassified as one share of common stock (the \"January Reverse Stock Split\"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted\nbasis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the\"October Reverse Stock Split\"\ntogether with the January Reverse Stock Split, the \"Reverse Stock Splits\"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock\nSplits."}],"balance_after":7904,"source":{"system":"sec-edgar","filing":"0001193125-25-337179","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337179/ownership.xml","form_type":"4"}},{"id":957623,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42011,"kind":"person","name":"Schabacker Marcus","position":1,"cik":"0001645282","reported_name":"Schabacker Marcus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T21:39:53.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock\nwere reclassified as one share of common stock (the \"January Reverse Stock Split\"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted\nbasis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the\"October Reverse Stock Split\"\ntogether with the January Reverse Stock Split, the \"Reverse Stock Splits\"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock\nSplits."}],"balance_after":7900,"source":{"system":"sec-edgar","filing":"0001193125-25-337178","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337178/ownership.xml","form_type":"4"}},{"id":957622,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T21:38:51.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":60296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term\nIncentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs\nwill vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any\nremaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the \"Reverse Stock Split\"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":70355,"source":{"system":"sec-edgar","filing":"0001193125-25-337175","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337175/ownership.xml","form_type":"4"}},{"id":957621,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42013,"kind":"person","name":"WEBB MICHAEL D","position":1,"cik":"0001239463","reported_name":"WEBB MICHAEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T21:37:53.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such\nshares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock\nwere reclassified as one share of common stock (the \"January Reverse Stock Split\"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted\nbasis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the\"October Reverse Stock Split\"\ntogether with the January Reverse Stock Split, the \"Reverse Stock Splits\"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock\nSplits."}],"balance_after":7898,"source":{"system":"sec-edgar","filing":"0001193125-25-337172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337172/ownership.xml","form_type":"4"}},{"id":957620,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42016,"kind":"person","name":"Coveney Kevin Michael","position":1,"cik":"0001967056","reported_name":"Coveney Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-30T21:37:07.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":40198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term\nIncentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs\nwill vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any\nremaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the \"Reverse Stock Split\"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":47413,"source":{"system":"sec-edgar","filing":"0001193125-25-337171","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000119312525337171/ownership.xml","form_type":"4"}},{"id":1152880,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42016,"kind":"person","name":"Coveney Kevin Michael","position":1,"cik":"0001967056","reported_name":"Coveney Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-05-12T21:00:20.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":74150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the \"Reverse Stock Split\"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":86584,"source":{"system":"sec-edgar","filing":"0001415889-25-012679","document":"form4-05122025_050505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588925012679/form4-05122025_050505.xml","form_type":"4"}},{"id":1152879,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF INNOVATION OFFICER"}}],"security":"Common Stock","published_at":"2025-05-12T21:00:16.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":24717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the \"Reverse Stock Split\"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":33058,"source":{"system":"sec-edgar","filing":"0001415889-25-012678","document":"form4-05122025_050503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588925012678/form4-05122025_050503.xml","form_type":"4"}},{"id":1152878,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-12T21:00:06.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":98866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the \"Reverse Stock Split\"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":120711,"source":{"system":"sec-edgar","filing":"0001415889-25-012677","document":"form4-05122025_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588925012677/form4-05122025_050501.xml","form_type":"4"}},{"id":1387829,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42010,"kind":"person","name":"DeWitt Sheila","position":1,"cik":"0002025032","reported_name":"DeWitt Sheila","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T23:23:08.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":27845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":27845,"source":{"system":"sec-edgar","filing":"0001415889-24-025063","document":"form4-10112024_111005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025063/form4-10112024_111005.xml","form_type":"4"}},{"id":1387828,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42012,"kind":"person","name":"Kegler George A.","position":1,"cik":"0001761753","reported_name":"Kegler George A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T23:21:18.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":47733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":48053,"source":{"system":"sec-edgar","filing":"0001415889-24-025061","document":"form4-10112024_111015.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025061/form4-10112024_111015.xml","form_type":"4"}},{"id":1387827,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42011,"kind":"person","name":"Schabacker Marcus","position":1,"cik":"0001645282","reported_name":"Schabacker Marcus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T23:18:57.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":47733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":48053,"source":{"system":"sec-edgar","filing":"0001415889-24-025059","document":"form4-10112024_111054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025059/form4-10112024_111054.xml","form_type":"4"}},{"id":1387826,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42013,"kind":"person","name":"WEBB MICHAEL D","position":1,"cik":"0001239463","reported_name":"WEBB MICHAEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T23:16:29.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":47733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":47733,"source":{"system":"sec-edgar","filing":"0001415889-24-025057","document":"form4-10112024_111026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025057/form4-10112024_111026.xml","form_type":"4"}},{"id":1387825,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42015,"kind":"person","name":"PASQUALONE FRANK","position":1,"cik":"0001597334","reported_name":"PASQUALONE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-11T23:14:11.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":47733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the \"Plan\"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":48733,"source":{"system":"sec-edgar","filing":"0001415889-24-025055","document":"form4-10112024_111008.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025055/form4-10112024_111008.xml","form_type":"4"}},{"id":1387824,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-10-11T23:11:01.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":161633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":335829,"source":{"system":"sec-edgar","filing":"0001415889-24-025052","document":"form4-10112024_111058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025052/form4-10112024_111058.xml","form_type":"4"}},{"id":1387823,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF INNOVATION OFFICER"}}],"security":"Common Stock","published_at":"2024-10-11T23:08:12.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":130856,"source":{"system":"sec-edgar","filing":"0001415889-24-025050","document":"form4-10112024_111008.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025050/form4-10112024_111008.xml","form_type":"4"}},{"id":1387813,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42016,"kind":"person","name":"Coveney Kevin Michael","position":1,"cik":"0001967056","reported_name":"Coveney Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-11T23:06:41.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":186500,"source":{"system":"sec-edgar","filing":"0001415889-24-025048","document":"form4-10112024_111038.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924025048/form4-10112024_111038.xml","form_type":"4"}},{"id":1620609,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-26T21:53:50.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":174196,"source":{"system":"sec-edgar","filing":"0001415889-24-005259","document":"form4-02262024_090238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924005259/form4-02262024_090238.xml","form_type":"4"}},{"id":1620608,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF INNOVATION OFFICER"}}],"security":"Common Stock","published_at":"2024-02-26T21:47:58.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":90856,"source":{"system":"sec-edgar","filing":"0001415889-24-005253","document":"form4-02262024_090248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924005253/form4-02262024_090248.xml","form_type":"4"}},{"id":1620607,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42016,"kind":"person","name":"Coveney Kevin Michael","position":1,"cik":"0001967056","reported_name":"Coveney Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-26T21:42:03.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."}],"balance_after":86500,"source":{"system":"sec-edgar","filing":"0001415889-24-005251","document":"form4-02262024_090246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588924005251/form4-02262024_090246.xml","form_type":"4"}},{"id":1778114,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42015,"kind":"person","name":"PASQUALONE FRANK","position":1,"cik":"0001597334","reported_name":"PASQUALONE FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T21:34:00.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.14,"value":2140.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001415889-23-013430","document":"form4-09192023_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000141588923013430/form4-09192023_090952.xml","form_type":"4"}},{"id":1955370,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42016,"kind":"person","name":"Coveney Kevin Michael","position":1,"cik":"0001967056","reported_name":"Coveney Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-14T23:24:03.000Z","date":"2023-03-13","kind":"grant","acquired":true,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents restricted stock units (the \"RSUs\") granted to the reporting person. For each vested RSU, the reporting person will be entitled to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on March 13, 2024."}],"balance_after":26500,"source":{"system":"sec-edgar","filing":"0001493152-23-007662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223007662/ownership.xml","form_type":"4"}},{"id":2044230,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Innovation Officer"}}],"security":"Common Stock","published_at":"2023-01-27T22:05:32.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal installments, with the first installment vesting upon the one year anniversary of the date of issuance."}],"balance_after":40865,"source":{"system":"sec-edgar","filing":"0001493152-23-002802","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002802/ownership.xml","form_type":"4"}},{"id":2044229,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President of Innovation"}}],"security":"Common Stock","published_at":"2023-01-27T22:05:31.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance."}],"balance_after":35802,"source":{"system":"sec-edgar","filing":"0001493152-23-002801","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002801/ownership.xml","form_type":"4"}},{"id":2044228,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117609,"kind":"person","name":"Kanubaddi Avani","position":1,"cik":"0001838498","reported_name":"Kanubaddi Avani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2023-01-27T22:05:26.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 38,346 restricted stock units previously reported on Table II."}],"balance_after":48346,"source":{"system":"sec-edgar","filing":"0001493152-23-002800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002800/ownership.xml","form_type":"4"}},{"id":2044227,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-27T22:05:22.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance."}],"balance_after":74196,"source":{"system":"sec-edgar","filing":"0001493152-23-002799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002799/ownership.xml","form_type":"4"}},{"id":2046804,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:31.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and $143.50, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,633 shares previously held through the Hagel 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":23802,"source":{"system":"sec-edgar","filing":"0001493152-23-002449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002449/ownership.xml","form_type":"4"}},{"id":2046803,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:31.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":1021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received the RSUs as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,633 shares previously held through the Hagel 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":13302,"source":{"system":"sec-edgar","filing":"0001493152-23-002449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002449/ownership.xml","form_type":"4"}},{"id":2046802,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:29.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and $143.50, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,633 shares previously held through the Facchini 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":23856,"source":{"system":"sec-edgar","filing":"0001493152-23-002452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002452/ownership.xml","form_type":"4"}},{"id":2046801,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:29.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":1021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received the restricted stock units (RSUs) as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,633 shares previously held through the Facchini 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":13356,"source":{"system":"sec-edgar","filing":"0001493152-23-002452","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002452/ownership.xml","form_type":"4"}},{"id":2046800,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:28.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and 143.50, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 13,822 shares previously held through the Tucker 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":30196,"source":{"system":"sec-edgar","filing":"0001493152-23-002453","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002453/ownership.xml","form_type":"4"}},{"id":2046799,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:28.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":1374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received the RSUs as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 13,822 shares previously held through the Tucker 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":15196,"source":{"system":"sec-edgar","filing":"0001493152-23-002453","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002453/ownership.xml","form_type":"4"}},{"id":2427128,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":131121,"kind":"person","name":"Ward Carter Julian","position":1,"cik":"0001467874","reported_name":"Ward Carter Julian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-25T21:57:13.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":744429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively."}],"balance_after":744429,"derivative":{"underlying":"Common Stock","underlying_shares":744429},"source":{"system":"sec-edgar","filing":"0001493152-22-002203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315222002203/ownership.xml","form_type":"4"}},{"id":2427127,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117609,"kind":"person","name":"Kanubaddi Avani","position":1,"cik":"0001838498","reported_name":"Kanubaddi Avani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2022-01-25T21:53:45.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":1127787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively."}],"balance_after":1127787,"derivative":{"underlying":"Common Stock","underlying_shares":1127787},"source":{"system":"sec-edgar","filing":"0001493152-22-002201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315222002201/ownership.xml","form_type":"4"}},{"id":2540987,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Warrants","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":1329,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 5,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":1329,"derivative":{"exercise_price":2.82,"exercise_date":"2021-09-16","expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":1329},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540986,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Warrants","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family."}],"balance_after":531602,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":531602},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540985,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Warrants","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":79740,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":79740,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":79740},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540984,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Options","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":99675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation."}],"balance_after":99675,"derivative":{"exercise_price":1.88,"exercise_date":"2021-09-16","expiration_date":"2026-04-05","underlying":"Common Stock","underlying_shares":99675},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540983,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family."}],"balance_after":531602,"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540982,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":82398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 310,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."}],"balance_after":82398,"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2541986,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Warrants","published_at":"2021-10-15T23:12:32.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":2658,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 10,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":2658,"derivative":{"exercise_price":2.82,"exercise_date":"2021-09-16","expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":2658},"source":{"system":"sec-edgar","filing":"0001493152-21-025625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025625/ownership.xml","form_type":"4"}},{"id":2541985,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Warrants","published_at":"2021-10-15T23:12:32.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held indirectly through the Facchini 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Facchini and his family."}],"balance_after":531602,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":531602},"source":{"system":"sec-edgar","filing":"0001493152-21-025625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025625/ownership.xml","form_type":"4"}},{"id":2541984,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Warrants","published_at":"2021-10-15T23:12:32.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":79740,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":79740,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":79740},"source":{"system":"sec-edgar","filing":"0001493152-21-025625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025625/ownership.xml","form_type":"4"}},{"id":2541983,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2021-10-15T23:12:32.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":99675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation."}],"balance_after":99675,"derivative":{"exercise_price":1.88,"exercise_date":"2021-09-16","expiration_date":"2026-04-05","underlying":"Common Stock","underlying_shares":99675},"source":{"system":"sec-edgar","filing":"0001493152-21-025625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025625/ownership.xml","form_type":"4"}},{"id":2541982,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-15T23:12:32.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held indirectly through the Facchini 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Facchini and his family."}],"balance_after":531602,"source":{"system":"sec-edgar","filing":"0001493152-21-025625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025625/ownership.xml","form_type":"4"}},{"id":2541981,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42009,"kind":"person","name":"Facchini Peter J.","position":1,"cik":"0001883966","reported_name":"Facchini Peter J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-15T23:12:32.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":85056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 320,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."}],"balance_after":85056,"source":{"system":"sec-edgar","filing":"0001493152-21-025625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025625/ownership.xml","form_type":"4"}},{"id":2544947,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrants","published_at":"2021-10-12T22:15:12.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":13290,"ownership":{"direct":false,"nature":"See footenote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family."}],"balance_after":13290,"derivative":{"exercise_price":2.82,"exercise_date":"2021-09-16","expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":13290},"source":{"system":"sec-edgar","filing":"0001493152-21-025237","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025237/ownership.xml","form_type":"4/A","original_submission_date":"2021-09-27"}},{"id":2544946,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrants","published_at":"2021-10-12T22:15:12.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footenote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family."}],"balance_after":531602,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":531602},"source":{"system":"sec-edgar","filing":"0001493152-21-025237","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025237/ownership.xml","form_type":"4/A","original_submission_date":"2021-09-27"}},{"id":2544945,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrants","published_at":"2021-10-12T22:15:12.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":132901,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":132901,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":132901},"source":{"system":"sec-edgar","filing":"0001493152-21-025237","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025237/ownership.xml","form_type":"4/A","original_submission_date":"2021-09-27"}},{"id":2544944,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-12T22:15:12.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":691083,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family."}],"balance_after":691083,"source":{"system":"sec-edgar","filing":"0001493152-21-025237","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025237/ownership.xml","form_type":"4/A","original_submission_date":"2021-09-27"}},{"id":2559334,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrants","published_at":"2021-09-27T20:35:06.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":13290,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker."}],"balance_after":13290,"derivative":{"exercise_price":2.82,"exercise_date":"2021-09-16","expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":13290},"source":{"system":"sec-edgar","filing":"0001493152-21-023865","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221023865/ownership.xml","form_type":"4"}},{"id":2559333,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrants","published_at":"2021-09-27T20:35:06.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":664503,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker."}],"balance_after":664503,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":664503},"source":{"system":"sec-edgar","filing":"0001493152-21-023865","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221023865/ownership.xml","form_type":"4"}},{"id":2559332,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-09-27T20:35:06.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":199351,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for options to acquire 750,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation."}],"balance_after":199351,"derivative":{"exercise_price":1.88,"exercise_date":"2021-09-16","expiration_date":"2026-04-05","underlying":"Common Stock","underlying_shares":199351},"source":{"system":"sec-edgar","filing":"0001493152-21-023865","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221023865/ownership.xml","form_type":"4"}},{"id":2559331,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42014,"kind":"person","name":"Tucker Joseph Edward","position":1,"cik":"0001883914","reported_name":"Tucker Joseph Edward","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-09-27T20:35:06.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":691083,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker."}],"balance_after":691083,"source":{"system":"sec-edgar","filing":"0001493152-21-023865","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221023865/ownership.xml","form_type":"4"}},{"id":2559330,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":135224,"kind":"person","name":"Thompson Bradley George","position":1,"cik":"0001883869","reported_name":"Thompson Bradley George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-09-27T20:32:51.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":53160,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for options to acquire 200,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation."}],"balance_after":53160,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2026-04-05","underlying":"Common Stock","underlying_shares":53160},"source":{"system":"sec-edgar","filing":"0001493152-21-023862","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221023862/ownership.xml","form_type":"4"}},{"id":2762601,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":140634,"kind":"person","name":"LIND DOUGLAS","position":1,"cik":"0001181206","reported_name":"LIND DOUGLAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T21:26:55.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":2265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the \"Plan\"). Such shares vested in full on the date of grant."}],"balance_after":2265,"source":{"system":"sec-edgar","filing":"0001493152-21-007899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221007899/ownership.xml","form_type":"4"}},{"id":2804174,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":70686,"kind":"person","name":"Van Buiten John","position":1,"cik":"0001838457","reported_name":"Van Buiten John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-08T21:15:50.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the \"Plan\"). Such shares shall vest in full on December 31, 2021, if the stock price of the issuer equals or exceeds $4.64, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 25,000 unvested shares of restricted stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001493152-21-005576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221005576/ownership.xml","form_type":"4"}},{"id":2856185,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":142577,"kind":"person","name":"Mayer Solomon","position":1,"cik":"0001533641","reported_name":"Mayer Solomon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T00:48:36.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":15957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the \"Plan\"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":15957,"source":{"system":"sec-edgar","filing":"0001493152-21-004181","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221004181/ownership.xml","form_type":"4"}},{"id":2856184,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42012,"kind":"person","name":"Kegler George A.","position":1,"cik":"0001761753","reported_name":"Kegler George A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T00:35:23.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":15957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the \"Plan\"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":15957,"source":{"system":"sec-edgar","filing":"0001493152-21-004178","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221004178/ownership.xml","form_type":"4"}},{"id":2856183,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":42011,"kind":"person","name":"Schabacker Marcus","position":1,"cik":"0001645282","reported_name":"Schabacker Marcus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-18T00:32:13.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":15957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the \"Plan\"). Such shares shall vest in full on December 30, 2021, or the one-year anniversary of the date on which the reporting person commenced providing services to the issuer as a member of its board of directors, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement."}],"balance_after":15957,"source":{"system":"sec-edgar","filing":"0001493152-21-004176","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221004176/ownership.xml","form_type":"4"}},{"id":2856182,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":71179,"kind":"person","name":"Johnson David Ian","position":1,"cik":"0001563432","reported_name":"Johnson David Ian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman"}}],"security":"Restricted Stock Units","published_at":"2021-02-18T00:29:29.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":53192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan (the \"Plan\"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in tranches based on the achievement of certain Company and individual performance goals in the 2021 calendar year established by the compensation committee of the board of directors of the Company for each such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in tranches based on the achievement of certain Company and individual performance goals in the 2021 calendar year established by the compensation committee of the board of directors of the Company for each such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan."}],"balance_after":1368999,"derivative":{"underlying":"Common Stock","underlying_shares":53192},"source":{"system":"sec-edgar","filing":"0001493152-21-004174","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221004174/ownership.xml","form_type":"4"}},{"id":2856181,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":71179,"kind":"person","name":"Johnson David Ian","position":1,"cik":"0001563432","reported_name":"Johnson David Ian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman"}}],"security":"Restricted Stock Units","published_at":"2021-02-18T00:29:29.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":1315807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan (the \"Plan\"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan."}],"balance_after":1315807,"derivative":{"underlying":"Common Stock","underlying_shares":1315807},"source":{"system":"sec-edgar","filing":"0001493152-21-004174","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221004174/ownership.xml","form_type":"4"}},{"id":2856180,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117609,"kind":"person","name":"Kanubaddi Avani","position":1,"cik":"0001838498","reported_name":"Kanubaddi Avani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-18T00:24:27.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":789484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan (the \"Plan\"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan."}],"balance_after":789484,"derivative":{"underlying":"Common Stock","underlying_shares":789484},"source":{"system":"sec-edgar","filing":"0001493152-21-004172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221004172/ownership.xml","form_type":"4"}},{"id":3675739,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":160597,"kind":"person","name":"Kelton Brent","position":1,"cik":"0001727392","reported_name":"Kelton Brent","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-02-05T21:19:39.000Z","date":"2019-02-05","kind":"other","acquired":true,"shares":986777,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares issued to the Reporting Person by the Issuer as payment of an earn-out in connection with the Issuer's acquisition of a wholly-owned subsidiary in March 2017, of which the Reporting Person had been an employee and shareholder."}],"balance_after":1079953,"source":{"system":"sec-edgar","filing":"0001140361-19-002484","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000114036119002484/form4.xml","form_type":"4"}},{"id":3757841,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":58850,"price":0.293,"value":17243.05,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2250000,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757840,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1850,"price":0.294,"value":543.9,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2308850,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757839,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":6657,"price":0.295,"value":1963.815,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2310700,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757838,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":200,"price":0.2951,"value":59.02,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2317357,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757837,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":15251,"price":0.3,"value":4575.3,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2317557,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757836,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":14119,"price":0.3003,"value":4239.9357,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2332808,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757835,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1515,"price":0.3006,"value":455.409,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2346927,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757834,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1500,"price":0.3011,"value":451.65,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2348442,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757833,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162313,"kind":"person","name":"Sikaria Lokesh","position":1,"cik":"0001758405","reported_name":"Sikaria Lokesh","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:45:12.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":58,"price":0.3028,"value":17.5624,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2349942,"source":{"system":"sec-edgar","filing":"0001607062-18-000437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000437/ownership.xml","form_type":"4"}},{"id":3757832,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":58850,"price":0.293,"value":17243.05,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2250000,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757831,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1850,"price":0.294,"value":543.9,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2308850,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757830,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":6657,"price":0.295,"value":1963.815,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2310700,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757829,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":200,"price":0.2951,"value":59.02,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2317357,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757828,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":15251,"price":0.3,"value":4575.3,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2317557,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757827,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":14119,"price":0.3003,"value":4239.9357,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2332808,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757826,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1515,"price":0.3006,"value":455.409,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2346927,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757825,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1500,"price":0.3011,"value":451.65,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2348442,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757824,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162312,"kind":"person","name":"Sikaria Chanda","position":1,"cik":"0001758404","reported_name":"Sikaria Chanda","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:47.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":58,"price":0.3028,"value":17.5624,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Chanda Sikaria is one of three trustees of The Lokesh Sikaria Trust Dated 12/14/2012, but Chanda Sikaria is not deemed a beneficial owner of the 2,250,000 shares of common stock held by The Lokesh Sikaria Trust Dated 12/14/2012 as the trustees can only act by majority vote, and no trustee could act individually to vote or sell shares held by The Lokesh Sikaria Trust Dated 12/14/2012."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes 2,250,000 shares of common stock beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012 as a member of the group. Chanda Sikaria expressly disclaims beneficial ownership in the shares beneficially owned by The Lokesh Sikaria Trust Dated 12/14/2012."}],"balance_after":2349942,"source":{"system":"sec-edgar","filing":"0001607062-18-000436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000436/ownership.xml","form_type":"4"}},{"id":3757823,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":58850,"price":0.293,"value":17243.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2250000,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757822,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1850,"price":0.294,"value":543.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2308850,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757821,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":6657,"price":0.295,"value":1963.815,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2310700,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757820,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":200,"price":0.2951,"value":59.02,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2317357,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757819,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":15251,"price":0.3,"value":4575.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2317557,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757818,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":14119,"price":0.3003,"value":4239.9357,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2332808,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757817,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1515,"price":0.3006,"value":455.409,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2346927,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757816,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":1500,"price":0.3011,"value":451.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2348442,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}},{"id":3757815,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":162311,"kind":"organization","name":"Lokesh Sikaria Trust Dated 12/14/2012","position":1,"cik":"0001758425","reported_name":"Lokesh Sikaria Trust Dated 12/14/2012","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-20T18:44:33.000Z","date":"2018-11-16","kind":"sale","acquired":false,"shares":58,"price":0.3028,"value":17.5624,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Lokesh Sikaria Trust Dated 12/14/2012 realized a short-swing profit of $719.35, which it will promptly forfeit to AMERI Holdings, Inc."}],"balance_after":2349942,"source":{"system":"sec-edgar","filing":"0001607062-18-000435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000160706218000435/ownership.xml","form_type":"4"}}],"next_cursor":"2018-11-20T18:44:33.000000Z,3757815"}